Elsevier

Veterinary Microbiology

Volume 210, October 2017, Pages 107-115
Veterinary Microbiology

Testing cathelicidin susceptibility of bacterial mastitis isolates: Technical challenges and data output for clinical isolates

https://doi.org/10.1016/j.vetmic.2017.08.022Get rights and content

Highlights

  • Well selected quality strains need to be included when testing MIC of AMPs.

  • BMAP-27 showed lower MICs for E. coli, BMAP-28 showed lower MICs for S. aureus.

  • Peptide- and also strain-specific variances occur in the technical procedure.

Abstract

Bovine mastitis caused by bacterial pathogens, such as Staphylococcus (S.) aureus and Escherichia (E.) coli, is a major economic problem in dairy industry. In order to limit the presence of multi-resistant bacteria in bovine mastitis, alternatives for the treatment with antibiotics are urgently needed. Antimicrobial peptides (AMPs) have recently been discussed as a potential new strategy against bacterial infections. They are key players in the innate immune system, as they can directly act against microorganisms or modulate the immune system. The aim of our study was to test S. aureus and E. coli mastitis isolates for their susceptibility to the bovine cathelicidins, BMAP-27 and BMAP-28.

Susceptibility testing was performed in analogy to the broth microdilution criteria described by the Clinical and Laboratory Standard Institute (CLSI) to determine MICs of 50 clinical S. aureus and 50 clinical E. coli isolates for BMAP-27 and BMAP-28. Based on the repetitive testing of four well-selected reference strains, the homogeneity of MIC variances for each peptide as well as the effect of temperature, oxygen level and plastic polymers on MIC testing was determined.

Statistical analysis revealed not only strong peptide-specific variances, but also strain-specific variances in the technical procedure. Finally, using this technique, susceptibility testing of the field isolates revealed statistically significant peptide-specific differences in the MICs. While BMAP-27 showed lower MICs for E. coli, BMAP-28 showed lower MICs for S. aureus. However, these results clearly illustrate the need of susceptibility testing of AMPs on several unrelated strains and not only on one selected test organism.

Introduction

Bovine mastitis is worldwide a leading problem in dairy industry which is often associated with severe suffering of diseased animals and high economic loss. The disease is caused by bacterial infections of the mammary glands – mainly caused by S. aureus, E. coli and/or various streptococcal species − and can have either a clinical or a subclinical appearance (Jadhav et al., 2013).

The problem of increasing bacterial resistance to antimicrobial agents with multi-resistant strains, e.g. livestock-associated methicillin-resistant S. aureus (LA-MRSA) (Feßler et al., 2010) or ESBL-producing E. coli (Freitag et al., 2015), requires alternative treatment strategies (Michael et al., 2015) to prevent any further increase in levels of resistance in bovine mastitis pathogens. Antimicrobial peptides (AMPs) are recently discussed as alternatives to antibiotics (Da Costa et al., 2015). Those peptides are key players of the innate immune system and are expressed in innate immune cells like neutrophils, mast cells, but also T-cells, natural killer cells (NK) cells and epithelial cells. AMPs can directly kill bacteria after they are phagocytosed or come in contact with secreted AMPs during the degranulation process (De Smet and Contreras, 2005). They are small, cationic molecules that can bind to bacterial membranes according to the low cholesterol content (Sood et al., 2008), but also according to the negative charge of the bacterial membrane (Oren et al., 1999). The cell specificity is given by the fact that mammalian cells contain higher amounts of cholesterol compared to bacteria and render the eukaryotic host cell more resistant to membrane disruption by the cationic AMPs (Brender et al., 2012). In addition to their ability to exert direct antimicrobial activity over a broad spectrum of pathogens, several AMPs have the capacity to modulate the immune response to control infection and inflammation and are therefore also often named host defense peptides (reviewed by Pachón-Ibáñez et al., 2017).

There are two classes of mammalian AMPs: the defensins and the cathelicidins. Cathelicidins are 12–80 amino acids long and contain a conserved N-terminal sequence – the cathelin region – and a C-terminal domain that is necessary for the antimicrobial activity and can vary in its length (Zanetti et al., 1995). In humans, only one cathelicidin (LL-37) was found, whereas in other species several AMPs are expressed. In cattle, two α-helical cathelicidins are BMAP-27 and BAMP-28 (Kościuczuk et al., 2012), which were shown to exhibit antimicrobial activity against Gram-positive as well as Gram-negative bacteria and even multi-drug resistant bacteria like LA-MRSA (Blodkamp et al., 2015; Zanetti et al., 2002) in the same mode of action as mCRAMP and LL-37 (Skerlavaj et al., 1996). Both peptides show a conserved N-terminal part, whereas the C-terminal part shows a tendency to non-conserved regions (Fig. 1). BMAP-27 and BMAP-28 exhibit the same overall hydrophobicity, especially in the C-terminus (Fig. 1). In our previous work (Blodkamp et al., 2015), both peptides were described as most potent comparing a pool of different mammalian cathelicidins against LA-MRSA isolates.

For testing the susceptibility of bacteria towards antimicrobial agents, minimal inhibitory concentration (MIC) assays are usually performed. This method is standardized for antimicrobial agents according to the recommendations of the CLSI. At present, harmonized protocols for testing the susceptibility of bacteria to AMPs are not available. MIC assays are often performed in analogy to the CLSI standards (CLSI VET01-A4, 2013), but the procedures applied were usually not characterized for the homogeneity/heterogeneity of the results obtained when comparing different peptides or different bacterial isolates.

In this study, we performed MIC assays according to CLSI-protocols for two bovine AMPs – BMAP-27 and BMAP-28 – with two selected clinical S. aureus isolates, one clinical E. coli isolate and one S. aureus laboratory strain. In addition, we tested different temperatures, oxygen level and plastic polymers in our setting. The peptide- and strain-specific homogeneity of the variances in the MIC data was analyzed. Finally, we determined the MIC values for BMAP-27 and BMAP-28 of 50 S. aureus and 50 E. coli field isolates and statistically compared peptide-specific MIC values of the two bacterial species.

Section snippets

Bacterial isolates

For the set-up of the technique, four selected reference strains – one clinical field isolate (S. aureus RD5, a clinical LA-MRSA isolate from cattle; Feßler et al., 2012), two strains derived from the American Type Culture Collection (ATCC®) (E. coli ATCC® 25922, S. aureus ATCC® 29213) and one laboratory strain (S. aureus Newman Δdlt) – were analyzed. The Δdlt mutant of S. aureus Newman is missing D-alanine substituents on its teichoid acids, which is important for bacterial resistance against

Strain and peptide specific tecnical variances of mic values

The MIC values of four selected reference strains were tested with two bovine AMPs – BMAP-27 and BMAP-28. Based on the repetitive (at least 13 times) testing of the selected strains, the homogeneity of MIC variances for each peptide was determined. In case of BMAP-27, the variances were homogenous for all four strains (Fig. 2A; p = 0.5839). In case of BMAP-28, the strains showed a tendency (p = 0.0632) to non-homogenous variances (Fig. 2C), which is reflected by the standard deviations (Fig. 2B and

Discussion

Antimicrobial susceptibility testing is a standard diagnostic tool in human as well as veterinary medicine. MIC determinations by quantitative assays, such as broth microdilution, agar dilution or E-test, provide the information how susceptible or how resistant a bacterium is to a specific antimicrobial agent and if there are appropriate clinical breakpoints available. To determine the MIC distribution for specific antimicrobial agents among bacterial pathogen of a certain species, a larger

Conclusion

Cathelicidins seem to be promising candidates as therapeutics besides other antimicrobial membrane-damaging peptides, such as nisin, which is already approved by both the EU and the United States Food and Drug Administration. However, most peptides, also nisin, exhibit differences in their antimicrobial activity when comparing different bacterial species (Campion et al., 2017). Our manuscript focusses on the MIC values of two bovine cathelicidins BMAP-27 and BMAP-28 towards field isolates from

 Funding

Melissa N. Langer was funded by a fellowship of the H. Wilhelm Schaumann Stiftung. She performed her thesis within the framework of the PhD program “Animal and Zoonotic Infections” of the Hannover Graduate School for Veterinary Pathobiology, Neuroinfectiology and translational Medicine (HGNI).

Competing interests

The authors have declared that no competing interests exist.

Acknowledgements

The authors thank Christina Schaal for technical assistance and Birthe Gericke for help with structural analysis of the tested peptides.

References (44)

  • N. Malanovic et al.

    Gram-positive bacterial cell envelopes: the impact on the activity of antimicrobial peptides

    Biochim. Biophys. Acta – Biomembr.

    (2016)
  • A. Peschel et al.

    Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides

    J. Biol. Chem.

    (1999)
  • B. Skerlavaj et al.

    Biological characterization of two novel cathelicidin-derived peptides and identification of structural requirements for their antimicrobial and cell lytic activities

    J. Biol. Chem.

    (1996)
  • R. Sood et al.

    Binding of LL-37 to model biomembranes: insight into target vs host cell recognition

    Biochim. Biophys. Acta – Biomembr.

    (2008)
  • M. Wu et al.

    Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane

    J. Biol. Chem.

    (1999)
  • M. Zanetti et al.

    Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain

    FEBS Lett.

    (1995)
  • J. Andrä et al.

    Significance of the cyclic structure and of arginine residues for the antibacterial activity of arenicin-1 and its interaction with phospholipid and lipopolysaccharide model membranes

    Biol. Chem.

    (2009)
  • R. Bals

    Epithelial antimicrobial peptides in host defense against infection

    Respir. Res.

    (2000)
  • S. Blodkamp et al.

    In vitro activity of human and animal cathelicidins against livestock-associated methicillin-resistant Staphylococcus aureus

    Vet. Microbiol.

    (2015)
  • J.R. Brender et al.

    Does cholesterol play a role in the bacterial selectivity of antimicrobial peptides?

    Front. Immunol.

    (2012)
  • Clinical and Laboratory Standards Institute (CLSI)

    Document VET01-S2: performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals

    Clin. Lab. Stand. Inst.

    (2013)
  • T. Cuperus et al.

    Protective effect of in ovo treatment with the chicken cathelicidin analog D-CATH-2 against avian pathogenic E. coli

    Sci. Rep.

    (2016)
  • View full text